ArticleThe American journal of tropical medicine and hygiene2018
Seroprevalence and Symptomatic Attack Rate of Chikungunya Virus Infection, United States Virgin Islands, 2014-2015.
Article in The American journal of tropical medicine and hygiene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Chikungunya seroprevalence in population-based studies: a systematic review and meta-analysis.Archives of public health = Archives belges de sante publique · 2023Pooled it
- Article
- Cost-effectiveness of chikungunya vaccination with the live attenuated vaccine in U.S. territories.NPJ vaccines · 2025Article
- Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns.Nature medicine · 2025Article
- Transfusion-transmitted infections: risks and mitigation strategies for Oropouche virus and other emerging arboviruses in Latin America and the Caribbean.Lancet regional health. Americas · 2025Review
- Acute Clinical Features and Persistence of Joint Pain in Probable Cases of Chikungunya Fever in Eritrea.Open access rheumatology : research and reviews · 2025Article
- Acute myocardial infarction in a young patient with Chikungunya: a case report.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Cryptic circulation of chikungunya virus in São Jose do Rio Preto, Brazil, 2015-2019.PLoS neglected tropical diseases · 2024Article
- Dynamics of chikungunya virus transmission in the first year after its introduction in Brazil: A cohort study in an urban community.PLoS neglected tropical diseases · 2023Article
- Epidemiology and Economic Burden of Chikungunya: A Systematic Literature Review.Tropical medicine and infectious disease · 2023Review
- Acceptability of a Chikungunya Virus Vaccine, United States Virgin Islands.The American journal of tropical medicine and hygiene · 2023Article
- Transmission of Chikungunya Virus in an Urban Slum, Brazil.Emerging infectious diseases · 2020Article
- Effects of Chikungunya virus immunity on Mayaro virus disease and epidemic potential.Scientific reports · 2019Article
- Chikungunya virus populations experience diversity- dependent attenuation and purifying intra-vector selection in Californian Aedes aegypti mosquitoes.PLoS neglected tropical diseases · 2019Article
- Rheumatic manifestations of chikungunya: emerging concepts and interventions.Nature reviews. Rheumatology · 2019Review
- Estimating the cost of illness and burden of disease associated with the 2014-2015 chikungunya outbreak in the U.S. Virgin Islands.PLoS neglected tropical diseases · 2019Article
- Autocidal gravid ovitraps protect humans from chikungunya virus infection by reducing Aedes aegypti mosquito populations.PLoS neglected tropical diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When introduced into a naïve population, chikungunya virus generally spreads rapidly, causing large outbreaks of fever and severe polyarthralgia. We randomly selected households in the U.S. Virgin Islands (USVI) to estimate seroprevalence and symptomatic attack rate for chikungunya virus infection at approximately 1 year following the introduction of the virus. Eligible household members were administered a questionnaire and tested for chikungunya virus antibodies. Estimated proportions were calibrated to age and gender of the population. We enrolled 509 participants. The weighted infection rate was 31% (95% confidence interval [CI]: 26-36%). Among those with evidence of chikungunya virus infection, 72% (95% CI: 65-80%) reported symptomatic illness and 31% (95% CI: 23-38%) reported joint pain at least once per week approximately 1 year following the introduction of the virus to USVI. Comparing rates from infected and noninfected study participants, 70% (95% CI: 62-79%) of fever and polyarthralgia and 23% (95% CI: 9-37%) of continuing joint pain in patients infected with chikungunya virus were due to their infection. Overall, an estimated 43% (95% CI: 33-52%) of the febrile illness and polyarthralgia in the USVI population during the outbreak was attributable to chikungunya virus and only 12% (95% CI: 7-17%) of longer term joint pains were attributed to chikungunya virus. Although the rates of infection, symptomatic disease, and longer term joint symptoms identified in USVI are similar to other outbreaks of the disease, a lower proportion of acute fever and joint pain was found to be attributable to chikungunya virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.